Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolution of mendelian randomization for investigating drug effects.

PLoS medicine - 1 Feb 2022

Gill Dipender, Burgess Stephen

Abstract excerpt

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues investigating the associations between genetically-proxied inhibition of antihypertensive drug targets and risk of common cancer subtypes using Mendelian randomization.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Antihypertensive Agents
Share to Blood Pressure

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Genetic Variation

Share to Genome-Wide Association Study

Share to Mendelian Randomization Analysis

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 35113864
DOI: 10.1371/journal.pmed.1003898
PMCID: PMC8812877

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolution of mendelian randomization for investigating drug effects.PMID 35113864Read ↗

Mendelian randomization for studying the effects of perturbing drug targetsSemantic proximity Read ↗

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.Semantic proximity Read ↗

Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19Semantic proximity Read ↗

Genetically-proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancersSemantic proximity Read ↗

Genetic drug target validation using Mendelian randomizationSemantic proximity Read ↗

Target Discovery for Drug Development Using Mendelian Randomization.Semantic proximity Read ↗

Mendelian randomization in (epi)genetic epidemiology: an effective tool to be handled with care.Semantic proximity Read ↗

Common pitfalls in drug target Mendelian randomization and how to avoid them.Semantic proximity Read ↗

Mendelian Randomization: How Genetics Is Pushing the Boundaries of Epidemiology to Identify New Causes of Heart DiseaseSemantic proximity Read ↗

Association of genetically proxied cancer-targeted drugs with cardiovascular diseases through Mendelian randomization analysis.Semantic proximity Read ↗

Mendelian Randomization: A Powerful Tool to Illuminate Pathophysiologic MechanismsSemantic proximity Read ↗

Genetically-proxied anti-diabetic drug target perturbation and risk of cancer: a Mendelian randomization analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.